文献速递肿瘤 PET/CT

倾向性评分分析:18-FDG PET/CT增强分期对食管癌手术患者的影响

Propensity score analysis of 18-FDG PET/CT-enhanced staging in patients undergoing surgery for esophageal cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-08-16

该研究纳入1998至2016年间接受食管切除术的496例食管癌患者(PET/CT前273例,PET/CT后223例),经倾向性评分协变量调整后分析PET/CT引入对生存和复发模式的影响。结果显示PET/CT后3年总生存率57.8% vs PET/CT前42.5%(p=0.004),复发率37.8% vs 51.4%(p=0.004),远处复发率27.0% vs 39.5%(p=0.006)。多因素分析显示PET/CT分期与总生存独立相关(HR 0.688,95%CI 0.53-0.89,p=0.004)。

要点

  • PET/CT后3年总生存率57.8%,PET/CT前42.5%(p=0.004)。
  • PET/CT后复发率37.8%,PET/CT前51.4%(p=0.004)。
  • PET/CT分期与总生存独立相关(HR 0.688,95%CI 0.53-0.89,p=0.004)。

核心结论

  • 增强PET/CT分期是食管切除术患者中的重要方法,且为与生存改善独立相关的因素。

研究设计与样本

  • 纵向队列研究,纳入1998至2016年间分期的食管癌患者,经倾向性评分协变量调整后,纳入496例接受食管切除术的患者(PET/CT前273例,PET/CT后223例)。

主要发现

  • PET/CT前3年总生存率为42.5%,PET/CT后为57.8%(卡方6.571,自由度1,p=0.004)。
  • 多因素分析显示,pT分期(HR 1.496,95%CI 1.28-1.75,p<0.0001)、pN分期(HR 1.114,95%CI 1.04-1.19,p=0.001)和PET/CT分期(HR 0.688,95%CI 0.53-0.89,p=0.004)与总生存独立相关。
  • PET/CT前复发125例(51.4%),PET/CT后复发74例(37.8%,p=0.004)。
  • PET/CT引入后远处复发可能性更低(PET/CT前39.5% vs PET/CT后27.0%,p=0.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PET/CT is now integral to the staging pathway for potentially curable esophageal cancer (EC), primarily to identify distant metastases undetected by computed tomography. The aim of this study was to analyze the effect of PET/CT introduction on survival and assess patterns of recurrence after esophagectomy. METHODS: A longitudinal cohort of EC patients staged between 1998 and 2016 were considered for inclusion. After co-variate adjustment using propensity scoring, a cohort of 496 patients (273 pre-PET/CT and 223 post-PET/CT) who underwent esophagectomy [median age 63 years (31-80), 395 males, 425 adenocarcinomas, 71 squamous cell carcinomas, 325 neoadjuvant therapy] were included. The primary outcome measure was overall survival (OS) based on intention to treat. RESULTS: Three-year OS pre-PET/CT was 42.5% compared with 57.8% post-PET/CT (Chi2 6.571, df 1, p = 0.004). On multivariable analysis, pT stage (HR 1.496 [95% CI 1.28-1.75], p < 0.0001), pN stage (HR 1.114 [95% CI 1.04-1.19], p = 0.001) and PET/CT staging (HR 0.688 [95% CI 0.53-0.89] p = 0.004) were independently associated with OS. Recurrent cancer was observed in 125 patients (51.4%) pre-PET/CT, compared with 74 patients post-PET/CT (37.8%, p = 0.004), and was less likely to be distant recurrence after PET/CT introduction (39.5 vs. 27.0%, p = 0.006). CONCLUSIONS: Enhanced PET/CT staging is an important modality and independent factor associated with improved survival in patients undergoing esophagectomy for cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Patel N, Foley KG, Powell AG, et al. Propensity score analysis of 18-FDG PET/CT-enhanced staging in patients undergoing surgery for esophageal cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 30116837. doi:10.1007/s00259-018-4118-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。